Previous 10 | Next 10 |
The European Medicines Agency (EMA) grants PRIME status to Adaptimmune Therapeutics' (NASDAQ: ADAP ) lead candidate ADP-A2M4, a SPEAR T-cell therapy, for the treatment of synovial sarcoma , a cancer of soft tissue such as muscle or ligaments. It also has Orphan Drug and Regenerative Med...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for...
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for Q2 2020, before the U.S. markets open on Thursday, August 6, ...
Cancer is one of the most challenging conditions for investigational therapies to target because malignant cells are frequently able to disguise themselves as healthy cells, thereby surpassing detection from the body's immune system. One biotech company that's gaining ground in this field is Ad...
Adaptimmune Therapeutics (NASDAQ: ADAP), a leader in cell therapy to treat cancer, recently closed an underwritten public offering of 20,500,000 of its American Depositary Shares (“ADSs”), including 3,075,000 additional ADSs in accordance with the full exercise of the over-allotm...
Adaptimmune Therapeutics (NASDAQ: ADAP) , a clinical-stage biotech, saw its shares gain an astounding 230% over the month of May, according to data from S&P Global Market Intelligence . The biotech's shares took flight late last month following a presentation at the Americ...
Adaptimmune Therapeutics (NASDAQ: ADAP ) has priced its public offering of 20.5M American Depositary Shares (“ADSs”) at $11.00/ADS, for expected gross proceeds of ~$225.5M. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, , Read more ...
Shares of the clinical-stage biotech Adaptimmune Therapeutics (NASDAQ: ADAP) fell by as much as 11% immediately out of the gate Monday morning. The drugmaker's stock kicked off the week off on a sour note thanks to a fairly large public offering consisting of 12.5 million of its America...
Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...
Adaptimmune Therapeutics (NASDAQ: ADAP ) intends to offer and sell 12.5M American Depositary Shares (ADSs) in a public offering. More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, , Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...